ScholarIQanswers from OpenAlex & ORCID
Baohui Han
ResearcherPublications, citations & collaboration network
Baohui Han is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Baohui Han have?
ScholarIQindexed works
Baohui Han has 686 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Baohui Han have?
ScholarIQcitation count
Baohui Han has 15,187 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Baohui Han?
ScholarIQh-index
Baohui Han has an h-index of 57 in OpenAlex.
What is the i10-index of Baohui Han?
ScholarIQi10-index
Baohui Han has an i10-index of 281 in OpenAlex.
What is the ORCID of Baohui Han?
ScholarIQorcid
The ORCID for Baohui Han is on the source record.
What is the OpenAlex record for Baohui Han?
ScholarIQopenalex
The OpenAlex for Baohui Han is on the source record.
What are the most-cited papers on Baohui Han?
ScholarIQmost cited works
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
Baohui Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Yizhuo Zhao, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, Robert Pirker, Kejun Nan, Faguang Jin, Jian Dong, Baolan Li, Yan Sun
Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: A systematic review and meta-analysis
Ping Gu, Yizhuo Zhao, Liyan Jiang, Wei Zhang, Xin Yu, Baohui Han
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma, Minghong Bi, Xiubao Ren, Jianying Zhou, Baolan Li, Yong Song, Jifeng Feng, Juan Li, Zhiyong He, Rui Zhou, Weimin Li, You Lü, Yingyi Wang, Lijun Wang, Nong Yang, Yan Zhang, Zhuang Yu, Yanqiu Zhao, Conghua Xie, Ying Cheng, Hui Zhou, Shuyan Wang, Donglei Zhu, Wen Zhang, Li Zhang
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non–Small-Cell Lung Cancer
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Xiaoqing Liu, Yunzhong Zhu, Shun Lü, Jifeng Feng, Jianxing He, Baohui Han, Jie Wang, Guoliang Jiang, Chunhong Hu, Hao Zhang, Gang Cheng, Xiangqun Song, You Lü, Hongming Pan, Wenjuan Zheng, Anny-Yue Yin
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
Ramaswamy Govindan, Aleksandra Szczęsna, Myung‐Ju Ahn, Claus-Peter Schneider, Pablo Fernando Gonzalez Mella, Fabrice Barlési, Baohui Han, Doina Ganea, Joachim von Pawel, Vladimir Vladimirov, Natalia Fadeeva, Ki Hyeong Lee, Takayasu Kurata, Li Zhang, Tomohide Tamura, Pieter E. Postmus, Jacek Jassem, Kenneth J. O’Byrne, Justin Kopit, Mingshun Li, Marina Tschaika, Martin Reck